<?xml version="1.0" encoding="UTF-8"?>
<p>Globally there are large inequalities in the diagnosis and treatment of PD. Generally, in low-middle income countries there is less access to PD medication and neurology services. In Sub-Saharan Africa there are very few neurologists and PD medications are unreliably supplied and expensive [
 <xref rid="ref150" ref-type="bibr">150, 151</xref>]. Studies comparing European PD patients to African PD patients conclude that patients in Africa have more severe disease but, despite this, are taking lower doses of levodopa. PD patients in Africa are symptomatic for longer periods before levodopa initiation and are more likely to be treated with anti-cholinergics and amantadine, compared with European patients who are more likely to be prescribed dopamine agonists, levodopa, COMT inhibitors and MAO-B inhibitors [
 <xref rid="ref036" ref-type="bibr">36, 152</xref>]. Another consideration is how geopolitical circumstances affect access to medication for chronic diseases, with countries such as Cuba in Central America, and Iran in the Middle East, likely struggling to supply essential PD drugs due to political sanctions.
</p>
